Advances in coeliac disease

Current Opinion in Gastroenterology

Volumn 30, Issue 2, 2014, Pages 154-162

  Lundin, Knut E A ^a,b   Sollid, Ludvig M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coeliac disease; Enteropathy; Gluten; Immunology; Treatment

Indexed keywords

CELIAC DISEASE; DIET, GLUTEN-FREE; GENETIC PREDISPOSITION TO DISEASE; GLUTENS; HUMANS;

EID: 84894061167     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000041     Document Type: Review

References (111)

1. Plaza-Izurieta L, Castellanos-Rubio A, Irastorza I, et al. Revisiting genome wide association studies (GWAS) in coeliac disease: Replication study in Spanish population and expression analysis of candidate genes. J Med Genet 2011; 48:493-496
2. Bondar C, Plaza-Izurieta L, Fernandez-Jimenez N, et al. THEMIS and PTPRK in celiac intestinal mucosa: Coexpression in disease and after in vitro gliadin challenge. Eur J Hum Genet 2013. [Epub ahead of print]
3. Parmar AS, Alakulppi N, Paavola-Sakki P, et al. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. Tissue Antigens 2012; 80:488-493
4. Einarsdottir E, Koskinen LL, De Kauwe AL, et al. Genome-wide analysis of extended pedigrees confirms IL2-IL21 linkage and shows additional regions of interest potentially influencing coeliac disease risk. Tissue Antigens 2011; 78:428-437
5. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43:1193-1201
6. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc Natl Acad Sci USA 2012; 109:1193-1198
7. Hunt KA, Mistry V, Bockett NA, et al. Negligible impact of rare autoimmunelocus coding-region variants on missing heritability. Nature 2013; 498:232-235
8. Stahl EA, Wegmann D, Trynka G, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012; 44:483-489
9. Cotsapas C, Voight BF, Rossin E, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 2011; 7:e1002254
10. Parmar AS, Lappalainen M, Paavola-Sakki P, et al. Association of celiac disease genes with inflammatory bowel disease in Finnish and Swedish patients. Genes Immun 2012; 13:474-480
11. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol 2013; 9:645-659
12. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14:661-673
13. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-Associated variation in regulatory DNA. Science 2012; 337:1190-1195
14. Roychoudhuri R, Hirahara K, Mousavi K, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013; 498:506-510
15. Kometani K, Nakagawa R, Shinnakasu R, et al. Repression of the transcription factor Bach2 contributes to predisposition of IgG1 memory B cells toward plasma cell differentiation. Immunity 2013; 39:136-147
16. Swaminathan S, Huang C, Geng H, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med 2013; 19:1014-1022
17. Gibbons DL, Abeler-Dorner L, Raine T, et al. Cutting edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential. J Immunol 2011; 187:2067-2071
18. Mubarak A, Spierings E, Wolters V, et al. Human leukocyte antigen DQ2.2 and celiac disease. J Pediatr Gastroenterol Nutr 2013; 56:428-430
19. Bodd M, Kim CY, Lundin KE, Sollid LM. T-cell response to gluten in patients with HLA-DQ2.2 reveals requirement of peptide-MHC stability in celiac disease. Gastroenterology 2012; 142:552-561
20. Ahn R, Ding YC, Murray J, et al. Association analysis of the extended MHC region in celiac disease implicates multiple independent susceptibility loci. PLoS One 2012; 7:e36926
21. Medrano LM, Dema B, Lopez-Larios A, et al. HLA and celiac disease susceptibility: New genetic factors bring open questions about the HLA influence and gene-dosage effects. PLoS One 2012; 7:e48403
22. Romanos J, Rosen A, Kumar V, et al. Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants. Gut 2013. [Epub ahead of print]
23. Junker Y, Zeissig S, Kim SJ, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of Toll-like receptor 4. J Exp Med 2012; 209:2395-2408
24. Palova-Jelinkova L, Danova K, Drasarova H, et al. Pepsin digest of wheat gliadin fraction increases production of IL-1beta via TLR4/MyD88/TRIF/ MAPK/NF-kappaB signaling pathway and an NLRP3 inflammasome activation. PLoS One 2013; 8:e62426
25. Broughton SE, Petersen J, Theodossis A, et al. Biased T cell receptor usage directed against human leukocyte antigen DQ8-restricted gliadin peptides is associated with celiac disease. Immunity 2012; 37:611-621
26. QiaoSW, Raki M, Gunnarsen KS, et al. Posttranslational modification of gluten shapes TCR usage in celiac disease. J Immunol 2011; 187:3064-3071
27. Han A, Newell EW, Glanville J, et al. Dietary gluten triggers concomitant activation of CD4' and CD8' alphabeta T cells and gammadelta T cells in celiac disease. Proc Natl Acad Sci USA 2013; 110:13073-13078
28. Camarca A, Radano G, Di Mase R, et al. Short wheat challenge is a reproducible in-vivo assay to detect immune response to gluten. Clin Exp Immunol 2012; 169:129-136
29. Sarra M, Cupi ML, Monteleone I, et al. IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunol 2013; 6:244-255
30. Van Leeuwen MA, Lindenbergh-Kortleve DJ, Raatgeep HC, et al. Increased production of interleukin-21, but not interleukin-17A, in the small intestine characterizes pediatric celiac disease. Mucosal Immunol 2013; 6:1202-1213
31. Di Niro R, Mesin L, Zheng NY, et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med 2012; 18:441-445
32. Iversen R, Di Niro R, Stamnaes J, et al. Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-Terminal epitopes not displayed on the surface of cells. J Immunol 2013; 190:5981-5991
33. Simon-Vecsei Z, Kiraly R, Bagossi P, et al. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc Natl Acad Sci USA 2012; 109:431-436
34. Lebreton C, Menard S, Abed J, et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 2012; 143:698-707
35. Abed J, Lebreton C, Champier G, et al. Abnormal apical-To-basal transport of dietary ovalbumin by secretory IgA stimulates a mucosal Th1 response. Mucosal Immunol 2013. [Epub ahead of print]
36. Ciccocioppo R, Bernardo ME, Russo ML, et al. Allogeneic hematopoietic stem cell transplantation may restore gluten tolerance in patients with celiac disease. J Pediatr Gastroenterol Nutr 2013; 56:422-427
37. Beitnes AC, Raki M, Brottveit M, et al. Rapid accumulation of CD14'CD11c' dendritic cells in gut mucosa of celiac disease after in vivo gluten challenge. PLoS One 2012; 7:e33556
38. Raki M, Beitnes AC, Lundin KE, et al. Plasmacytoid dendritic cells are scarcely represented in the human gut mucosa and are not recruited to the celiac lesion. Mucosal Immunol 2013; 6:985-992
39. Sanchez E, Donat E, Ribes-Koninckx C, et al. Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol 2013; 79:5472-5479
40. De Meij TG, Budding AE, Grasman ME, et al. Composition and diversity of the duodenal mucosa-Associated microbiome in children with untreated coeliac disease. Scand J Gastroenterol 2013; 48:530-536
41. Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:136-160
42. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43-52
43. Bai JC, Fried M, Corazza GR, et al. World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol 2013; 47:121-126
44. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656-676; quiz 677
45. Kochhar R, Sachdev S, Kochhar R, et al. Prevalence of coeliac disease in healthy blood donors: A study from north India. Dig Liver Dis 2012; 44:530-532
46. Makharia GK, Verma AK, Amarchand R, et al. Prevalence of celiac disease in the northern part of India: A community based study. J Gastroenterol Hepatol 2011; 26:894-900
47. Wang XQ, Liu W, Xu CD, et al. Celiac disease in children with diarrhea in 4 cities in China. J Pediatr Gastroenterol Nutr 2011; 53:368-370
48. Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 2013; 108:818-824
49. Murray JA, McLachlan S, Adams PC, et al. Association between celiac disease and iron deficiency in Caucasians, but not non-Caucasians. Clin Gastroenterol Hepatol 2013; 11:808-814
50. Whyte LA, Jenkins HR. The epidemiology of coeliac disease in South Wales: A 28-year perspective. Arch Dis Child 2013; 98:405-407
51. Dydensborg S, Toftedal P, Biaggi M, et al. Increasing prevalence of coeliac disease in Denmark: A linkage study combining national registries. Acta Paediatr 2012; 101:179-184
52. Kratzer W, Kibele M, Akinli A, et al. Prevalence of celiac disease in Germany: A prospective follow-up study. World J Gastroenterol 2013; 19:2612-2620
53. Lebwohl B, Green PH, Murray JA, Ludvigsson JF. Season of birth in a nationwide cohort of coeliac disease patients. Arch Dis Child 2013; 98: 48-51
54. Myleus A, Hernell O, Gothefors L, et al. Early infections are associated with increased risk for celiac disease: An incident case-referent study. BMC Pediatr 2012; 12:194
55. Card TR, Siffledeen J, West J, Fleming KM. An excess of prior irritable bowel syndrome diagnoses or treatments in celiac disease: Evidence of diagnostic delay. Scand J Gastroenterol 2013; 48:801-807
56. DeGaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: A diagnostic and therapeutic dilemma. Am J Gastroenterol 2013; 108:647-653
57. Pallav K, Leffler DA, Tariq S, et al. Noncoeliac enteropathy: The differential diagnosis of villous atrophy in contemporary clinical practice. Aliment Pharmacol Ther 2012; 35:380-390
58. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87:732-738
59. Arguelles-Grande C, Tennyson CA, Lewis SK, et al. Variability in small bowel histopathology reporting between different pathology practice settings: Impact on the diagnosis of coeliac disease. J Clin Pathol 2012; 65:242-247
60. Evans KE, Aziz I, Cross SS, et al. A prospective study of duodenal bulb biopsy in newly diagnosed and established adult celiac disease. Am J Gastroenterol 2011; 106:1837-1842
61. Lebwohl B, Kapel RC, Neugut AI, et al. Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointest Endosc 2011; 74:103-109
62. Not T, Ziberna F, Vatta S, et al. Cryptic genetic gluten intolerance revealed by intestinal antitransglutaminase antibodies and response to gluten-free diet. Gut 2011; 60:1487-1493
63. Zanini B, Caselani F, Magni A, et al. Celiac disease with mild enteropathy is not mild disease. Clin Gastroenterol Hepatol 2013; 11:253-258
64. Taavela J, Kurppa K, Collin P, et al. Degree of damage to the small bowel and serum antibody titers correlate with clinical presentation of patients with celiac disease. Clin Gastroenterol Hepatol 2013; 11:166-171
65. Klapp G, Masip E, Bolonio M, et al. Celiac disease: The new proposed ESPGHAN diagnostic criteria do work well in a selected population. J Pediatr Gastroenterol Nutr 2013; 56:251-256
66. Kurppa K, Salminiemi J, Ukkola A, et al. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. J Pediatr Gastroenterol Nutr 2012; 54:387-391
67. Popp A, Mihu M, Munteanu M, et al. Prospective antibody case finding of coeliac disease in type-1 diabetes children: Need of biopsy revisited. Acta Paediatr 2013; 102:e102-e106
68. Wakim-Fleming J, Pagadala MR, Lemyre MS, et al. Diagnosis of celiac disease in adults based on serology test results, without small-bowel biopsy. Clin Gastroenterol Hepatol 2013; 11:511-516
69. Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62:996-1004
70. Lahdeaho ML, Maki M, Laurila K, et al. Small-bowel mucosal changes and antibody responses after low-And moderate-dose gluten challenge in celiac disease. BMC Gastroenterol 2011; 11:129
71. Norström F, Sandström O, Lindholm L, Ivarsson A. A gluten-free diet effectively reduces symptoms and healthcare consumption in a Swedish celiac disease population. BMC Gastroenterol 2012; 12:125
72. Nordyke K, Norström F, Lindholm L, et al. Health-related quality of life in adolescents with screening-detected celiac disease, before and one year after diagnosis and initiation of gluten-free diet, a prospective nested casereferent study. BMC Public Health 2013; 13:142
73. Sainsbury K, Mullan B, Sharpe L. A randomized controlled trial of an online intervention to improve gluten-free diet adherence in celiac disease. Am J Gastroenterol 2013; 108:811-817
74. Hall NJ, Rubin GP, Charnock A. Intentional and inadvertent nonadherence in adult coeliac disease. A cross-sectional survey. Appetite 2013; 68:56-62
75. Hollon JR, Cureton PA, Martin ML, et al. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-Adherent nonresponsive celiac disease patients. BMC Gastroenterol 2013; 13:40
76. Comino I, Real A, Vivas S, et al. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. Am J Clin Nutr 2012; 95:670-677
77. Adriaanse MP, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther 2013; 37:482-490
78. Vreugdenhil AC, Wolters VM, Adriaanse MP, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011; 46:1435-1441
79. Tanner GJ, Colgrave ML, Blundell MJ, et al. Measuring hordein (gluten) in beer -A comparison of ELISA and mass spectrometry. PLoS One 2013; 8:e56452
80. Picariello G, Mamone G, Nitride C, et al. Shotgun proteome analysis of beer and the immunogenic potential of beer polypeptides. J Proteomics 2012; 75:5872-5882
81. Carroccio A, Mansueto P, Iacono G, et al. Nonceliac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity. Am J Gastroenterol 2012; 107:1898-1906
82. Volta U, Tovoli F, Cicola R, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol 2012; 46:680-685
83. Sapone A, Lammers KM, Casolaro V, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-Associated conditions: Celiac disease and gluten sensitivity. BMC Med 2011; 9:23
84. Brottveit M, Beitnes AC, Tollefsen S, et al. Mucosal cytokine response after short-Term gluten challenge in celiac disease and nonceliac gluten sensitivity. Am J Gastroenterol 2013; 108:842-850
85. Coburn JA, Vande Voort JL, Lahr BD, et al. Human leukocyte antigen genetics and clinical features of self-Treated patients on a gluten-free diet. J Clin Gastroenterol 2013; 47:828-833
86. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of glutenfree diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-911
87. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508-514
88. Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported nonceliac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145:320-328
89. Lau NM, Green PH, Taylor AK, et al. Markers of celiac disease and gluten sensitivity in children with autism. PLoS One 2013; 8:e66155
90. Croese J, Gaze ST, Loukas A. Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity. Int J Parasitol 2013; 43:275-282
91. Rauhavirta T, Oittinen M, Kivisto R, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-ofconcept study. J Clin Immunol 2013; 33:134-142
92. Pinier M, Fuhrmann G, Galipeau HJ, et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012; 142:316-325
93. Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012; 107:1554-1562
94. Kelly CP, Green PH, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebocontrolled study. Aliment Pharmacol Ther 2013; 37:252-262
95. Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: Results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012; 57:440-450
96. Moron B, Verma AK, Das P, et al. CYP3A4-catalyzed simvastatin metabolism as a noninvasive marker of small intestinal health in celiac disease. Am J Gastroenterol 2013; 108:1344-1351
97. Abu Daya H, Lebwohl B, Lewis SK, Green PH. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. Clin Gastroenterol Hepatol 2013; 11:1472-1477
98. Mollazadegan K, Sanders DS, Ludvigsson J, Ludvigsson JF. Long-Term coeliac disease influences risk of death in patients with type 1 diabetes. J Intern Med 2013; 274:273-280
99. Kiefte-de Jong JC, Jaddoe VW, Uitterlinden AG, et al. Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. Gastroenterology 2013; 144:726-735
100. Kabbani TA, Kelly CP, Betensky RA, et al. Patients with celiac disease have a lower prevalence of noninsulin-dependent diabetes mellitus and metabolic syndrome. Gastroenterology 2013; 144:912-917
101. Ludvigsson JF, West J, Ekbom A, Stephansson O. Reduced risk of breast, endometrial and ovarian cancer in women with celiac disease. Int J Cancer 2012; 131:E244-E250
102. Elfstrom P, Granath F, Ye W, Ludvigsson JF. Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease. Clin Gastroenterol Hepatol 2012; 10:30-36
103. Grainge MJ, West J, Solaymani-Dodaran M, et al. The long-Term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: A cohort study. Aliment Pharmacol Ther 2012; 35:730-739
104. Canavan C, Logan RF, Khaw KT, West J. No difference in mortality in undetected coeliac disease compared with the general population: A UK cohort study. Aliment Pharmacol Ther 2011; 34:1012-1019
105. Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80: 1740-1745
106. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013; 37:332-339
107. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: A population-based cohort study. Ann Intern Med 2013; 159:169-175
108. Schmitz F, Tjon JM, Lai Y, et al. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II. Gut 2013; 62:509-519
109. Tack GJ, van Asseldonk DP, van Wanrooij RL, et al. Tioguanine in the treatment of refractory coeliac disease -A single centre experience. Aliment Pharmacol Ther 2012; 36:274-281
110. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study. Dig Liver Dis 2013; 45:377-384
111. Waldmann TA, Conlon KC, Stewart DM, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013; 121:476-484